A Phase I/IIA Study to Assess Safety, Tolerability and Preliminary Activity of the Combination of FAK (Defactinib) and PD-1 (Pembrolizumab) Inhibition in Patients With Advanced Solid Malignancies (FAK-PD1)
Phase of Trial: Phase I/II
Latest Information Update: 12 Aug 2017
At a glance
- Drugs Defactinib (Primary) ; Pembrolizumab (Primary)
- Indications Adenocarcinoma; Mesothelioma; Non-small cell lung cancer; Pancreatic cancer; Solid tumours
- Focus Adverse reactions
- 30 May 2017 Planned End Date changed from 1 Dec 2020 to 1 Dec 2021.
- 30 May 2017 Planned primary completion date changed from 1 Jun 2018 to 1 May 2019.
- 30 May 2017 Status changed from not yet recruiting to recruiting.